Clinical Trials
4 trialsNCT02253992 2020-10-05
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01471210 2017-04-19
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Bristol-Myers Squibb
Phase 1 Completed
NCT01775631 2017-03-31
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Bristol-Myers Squibb
Phase 1 Completed
NCT02420938 2016-12-06
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Withdrawn